Werewolf Therapeutics Reports Q2 2025 Financial Results

Werewolf Therapeutics ( (HOWL) ) has shared an update.

Werewolf Therapeutics reported its second-quarter 2025 financial results and provided a business update, highlighting progress in their clinical trials and product development. The company is on track for an interim data readout of its WTX-124 Phase 1/1b trial in late 2025, targeting melanoma and renal cell carcinoma. They also plan to engage with the FDA regarding potential pathways for WTX-124. Additionally, Werewolf introduced WTX-1011, a new T-cell engager candidate for prostate cancer, and announced plans to nominate another candidate by year-end. Financially, the company reported a net loss of $18 million for the quarter, with sufficient cash to fund operations into late 2026.

The most recent analyst rating on (HOWL) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.

Spark’s Take on HOWL Stock

According to Spark, TipRanks’ AI Analyst, HOWL is a Neutral.

The overall score reflects significant financial challenges and the risk of delisting, which are major concerns for investors. While there is some short-term technical strength, the negative valuation metrics and corporate event risks weigh heavily on the stock’s outlook.

To see Spark’s full report on HOWL stock, click here.

More about Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing therapeutics that stimulate the immune system to treat cancer and other immune-mediated conditions. The company leverages its proprietary PREDATOR® platform to create conditionally activated INDUKINE™ and INDUCER™ molecules, aiming to address the limitations of conventional immune therapies. Their advanced clinical-stage products include WTX-124 and WTX-330, targeting solid tumors.

Average Trading Volume: 508,701

Technical Sentiment Signal: Sell

Current Market Cap: $53.85M

For an in-depth examination of HOWL stock, go to TipRanks’ Overview page.